Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13
TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed? or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis, announced today that it will host a conference call and webcast on Wednesday, March 13, 2018, to provide an update on current developments with respect to its clinical programs for Aramchol(TM) and to discuss financial results for the quarter and year ended December 31, 2018.
Conference Call & Webcast:
Wednesday, March 13th @ 8:30am Eastern Time.
Within the US: 877-425-9470
Outside the US: 201-389-0878
From Israel: 1 809 406 247
Conference ID: 13687890
Webcast: http://public.viavid.com/index.php?id=133389
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations. Galmed recently announced top-line results of the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase 2b clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing for an end of Phase 2b meeting with the FDA to discuss the results of the ARREST Study and a Phase 3/4 study protocol, with a view to initiating a Phase 3/4 clinical study of Aramchol in 2019.
View original content to download multimedia:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-fourth-quarter-and-year-end-2018-financial-results-and-provide-business-update-on-wednesday-march-13-300807551.html
SOURCE Galmed Pharmaceuticals Ltd.
